These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11701896)

  • 41. [Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
    Pinessi L; Sabbatini F; De Mattei M; Gentile S
    Minerva Med; 1984 Nov; 75(42):2539-42. PubMed ID: 6096765
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
    Caudle WM; Colebrooke RE; Emson PC; Miller GW
    Trends Neurosci; 2008 Jun; 31(6):303-8. PubMed ID: 18471904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcium homeostasis, free radical formation, and trophic factor dependence mechanisms in Parkinson's disease.
    De Erausquin GA; Costa E; Hanbauer I
    Pharmacol Rev; 1994 Dec; 46(4):467-82. PubMed ID: 7899474
    [No Abstract]   [Full Text] [Related]  

  • 44. Parkinson's disease: etiological considerations.
    Barbeau A
    Res Publ Assoc Res Nerv Ment Dis; 1976; 55():281-92. PubMed ID: 1005903
    [No Abstract]   [Full Text] [Related]  

  • 45. [Parkinson's disease 20 years later].
    Guillard A
    Presse Med; 1987 Oct; 16(32):1565-6. PubMed ID: 2958829
    [No Abstract]   [Full Text] [Related]  

  • 46. Oxidative damage in Parkinson's disease.
    Sherer TB; Greenamyre JT
    Antioxid Redox Signal; 2005; 7(5-6):627-9. PubMed ID: 15890006
    [No Abstract]   [Full Text] [Related]  

  • 47. Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
    Wallace DC; Shoffner JM; Watts RL; Juncos JL; Torroni A
    Ann Neurol; 1992 Jul; 32(1):113-4. PubMed ID: 1642467
    [No Abstract]   [Full Text] [Related]  

  • 48. The bioengineering of stem cells to create dopamine replacement neurons is not the solution for Parkinson's.
    Carey RJ; Carey JL
    Pharmacol Biochem Behav; 2017 Dec; 163():36-37. PubMed ID: 29066358
    [No Abstract]   [Full Text] [Related]  

  • 49. Mechanisms of Parkinson's disease.
    Br Med J; 1978 Apr; 1(6117):872-3. PubMed ID: 25109
    [No Abstract]   [Full Text] [Related]  

  • 50. [Pathophysiological mechanisms of adverse effects from levodopa therapy].
    Fahn S
    Rinsho Shinkeigaku; 1982 Dec; 22(12):1088-91. PubMed ID: 7168944
    [No Abstract]   [Full Text] [Related]  

  • 51. Comment on the commonality of manganese neurotoxicity and Parkinson's disease.
    Graham DG
    Neurotoxicology; 1981 Oct; 2(2):387-8. PubMed ID: 7198760
    [No Abstract]   [Full Text] [Related]  

  • 52. [Biochemical aspects of involuntary movements (author's transl)].
    Nakamura S; Kameyama M
    No To Shinkei; 1981 Dec; 33(12):1177-85. PubMed ID: 7034752
    [No Abstract]   [Full Text] [Related]  

  • 53. Metallothionein and oxidation reactions in Parkinson's disease.
    Ebadi M; Pfeiffer RF; Murrin LC; Shiraga H
    Proc West Pharmacol Soc; 1991; 34():285-90. PubMed ID: 1788299
    [No Abstract]   [Full Text] [Related]  

  • 54. Dopamine 3-O-sulphate, an end product of L-dopa metabolism in Parkinson patients.
    Jenner WN; Rose FA
    Nature; 1974 Nov; 252(5480):237-8. PubMed ID: 4422149
    [No Abstract]   [Full Text] [Related]  

  • 55. [Dopamine and parkinsonism].
    Siegfried J
    Schweiz Med Wochenschr; 1968 Mar; 98(11):429-31. PubMed ID: 5700507
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term influence of levodopa on bone mass and growth hormone in postmenopausal women with Parkinson's disease.
    Rico H; Vazquez A; Cabranes JA; Cantizano L; Hernandez ER; Krisnik I; Varela de Seijas E
    Clin Neuropharmacol; 1987; 10(1):87-91. PubMed ID: 3815389
    [No Abstract]   [Full Text] [Related]  

  • 57. Parkinson's disease.
    Marsden CD
    Postgrad Med J; 1992 Jul; 68(801):538-43. PubMed ID: 1437950
    [No Abstract]   [Full Text] [Related]  

  • 58. Biochemistry of the hypothalamus in Parkinson's disease.
    Javoy-Agid F; Ruberg M; Pique L; Bertagna X; Taquet H; Studler JM; Cesselin F; Epelbaum J; Agid Y
    Neurology; 1984 May; 34(5):672-5. PubMed ID: 6143285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Excitatory amino acid antagonists and Parkinson's disease.
    Girault JA; Halpain S; Greengard P
    Trends Neurosci; 1990 Aug; 13(8):325-7. PubMed ID: 1699316
    [No Abstract]   [Full Text] [Related]  

  • 60. Synuclein Deficiency Decreases the Efficiency of Dopamine Uptake by Synaptic Vesicles.
    Ninkina NN; Tarasova TV; Chaprov KD; Goloborshcheva VV; Bachurin SO; Buchman VL
    Dokl Biochem Biophys; 2019 May; 486(1):168-170. PubMed ID: 31367813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.